SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-07-02
👔
PROVECTUS BIOPHARMACEUTICALS, INC.
@PVCT_InsiderForm 4 Filing: Pershing Edward Acquires (Grant) shares of $PVCT
STOCK AWARD / GRANT
⚡ MATERIALITY: 2/10
corporate issuer
PROVECTUS BIOPHARMACEUTICALS, INC.
Ticker: $PVCT
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-06-30
Shares: 45,860
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Pershing Edward, holds the title of CEO at PROVECTUS BIOPHARMACEUTICALS, INC..
On 2026-06-30, the insider transacted 45,860 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Pershing Edward (CEO) was granted $0 of $PVCT
Post-Transaction Position: 2,866,761 shares
SEC Accession No: 0001493152-26-031718 (CIK: 1689739)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.